JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy.
Leclercq G, Haegel H, Toso A, Zimmermann T, Green L, Steinhoff N, Sam J, Pulko V, Schneider A, Giusti AM, Challier J, Freimoser-Grundschober A, Larivière L, Odermatt A, Stern M, Umana P, Bacac M, Klein C.
Leclercq G, et al. Among authors: haegel h.
J Immunother Cancer. 2022 Jan;10(1):e003766. doi: 10.1136/jitc-2021-003766.
J Immunother Cancer. 2022.
PMID: 35064010
Free PMC article.